Exoduspoint Capital Management 13F: New $14M Stake in COGT

Exoduspoint Capital Takes New Stake in Cogent Biosciences

Exoduspoint Capital Management initiated a brand-new position in Cogent Biosciences, Inc. (NasdaqGS: COGT), picking up 372,175 shares during the period. The latest Form 13F filing filed with the SEC values the new holding at approximately $14.4 million based on the reported cost basis of $36.91 per share.

Inside the New Cogent Biosciences Holding

Because this transaction represents a brand-new stake, the fund did not previously own any shares of the biotechnology firm. The acquisition brings 372,175 shares into Exoduspoint's portfolio, reflecting an estimated value of $14.4 million at the time of the report. Filing documents provide a backward-looking snapshot of institutional activity and may not reflect current holdings.

Cogent Biosciences Stock Price and Market Standing

Shares of Cogent Biosciences change hands around $38.70. The stock trades between a 52-week low of $12.44 and a high of $43.73. With a market capitalization of roughly $5.55 billion, the clinical-stage biotech firm operates without a positive earnings per share figure, meaning a conventional price-to-earnings ratio is not applicable.

Wall Street Analysts Update Views on Cogent Biosciences

Research firms have kept a close eye on the company's clinical pipeline through recent months. On September 16, 2026, Wedbush reiterated its outperform rating and set a $55.00 price target. HC Wainwright & Co. followed on September 15, 2026, by reiterating a buy rating and a $55.00 target. Earlier in the summer, Piper Sandler maintained an overweight rating on August 17, 2026, while moving its target from $52.00 to $55.00. Guggenheim also maintained a buy rating on August 12, 2026, lifting its price target to $52.00 from $45.00. Across 11 total reviews, analysts hold a consensus strong buy rating with a mean price target of $55.82. <div></div>

Precision Therapies at Cogent Biosciences

Headquartered in Waltham, Massachusetts, Cogent Biosciences is a clinical-stage biotechnology company focused on treatments for genetically defined diseases. Its lead candidate, bezuclastinib, targets KIT mutations found in systemic mastocytosis and advanced gastrointestinal stromal tumors. The firm also develops other selective inhibitors targeting FGFR, ErbB2, and PI3Ka mutations.

Looking Ahead for Institutional Holdings

Investors tracking Exoduspoint Capital and other major funds will await subsequent SEC disclosures to see how these biotech positions evolve. The company has scheduled its next quarterly earnings update for November 3, 2026, which will bring further details on pipeline progress.